TY - JOUR T1 - Association between EGFR-TKI Resistance and Efficacy of Radiotherapy for Brain Metastases from <em>EGFR</em>-mutant Lung Adenocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 1649 LP - 1655 VL - 33 IS - 4 AU - HIDENARI HIRATA AU - KATSUMASA NAKAMURA AU - NAONOBU KUNITAKE AU - YOSHIYUKI SHIOYAMA AU - TOMONARI SASAKI AU - SAIJI OHGA AU - TAKESHI NONOSHITA AU - TADAMASA YOSHITAKE AU - KAORI ASAI AU - KOUJI INOUE AU - AKIRA NAGASHIMA AU - MINORU ONO AU - HIROSHI HONDA Y1 - 2013/04/01 UR - http://ar.iiarjournals.org/content/33/4/1649.abstract N2 - Aim: To clarify how patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma with acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) respond to radiotherapy (RT) for brain metastases. Patients and Methods: Forty-seven patients were divided into the following three groups: a TKI-naïve group with EGFR mutation (n=11), a TKI-resistant group with EGFR mutation (n=10), and an EGFR-wild-type group (n=26). Patients received stereotactic RT (n=23) or whole-brain RT (n=24). Results: The response rate for patients with TKI-resistant tumor at three months after RT tended to be lower (11%) than that of those who were TKI-naïve (82%, p=0.006) and for patients with wild-type EGFR (48%, p=0.10). On univariate analysis, central nervous system progression-free and overall survival were significantly shorter for patients with TKI-resistant tumors than for those who were TKI-naïve (p=0.018 and p=0.005, respectively). Multivariate analysis showed that TKI resistance was an independent predictor of poorer overall survival (p=0.011). Conclusion: Acquired resistance to TKIs appears to be associated with low efficacy of brain RT. ER -